Literature DB >> 18558855

Multiple sclerosis: an immune or neurodegenerative disorder?

Bruce D Trapp1, Klaus-Armin Nave.   

Abstract

Multiple sclerosis (MS) is an inflammatory-mediated demyelinating disease of the human central nervous system. The clinical disease course is variable, usually starts with reversible episodes of neurological disability in the third or fourth decade of life, and transforms into a disease of continuous and irreversible neurological decline by the sixth or seventh decade. We review data that support neurodegeneration as the major cause of irreversible neurological disability in MS patients. We question whether inflammatory demyelination is primary or secondary in the disease process and discuss the challenges of elucidating the cause of MS and developing therapies that will delay or prevent the irreversible and progressive neurological decline that most MS patients endure.

Entities:  

Mesh:

Year:  2008        PMID: 18558855     DOI: 10.1146/annurev.neuro.30.051606.094313

Source DB:  PubMed          Journal:  Annu Rev Neurosci        ISSN: 0147-006X            Impact factor:   12.449


  542 in total

1.  Mechanisms Involved in the Remyelinating Effect of Sildenafil.

Authors:  Daniela Díaz-Lucena; María Gutierrez-Mecinas; Beatriz Moreno; José Lupicinio Martínez-Sánchez; Paula Pifarré; Agustina García
Journal:  J Neuroimmune Pharmacol       Date:  2017-08-03       Impact factor: 4.147

2.  Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice.

Authors:  Grazyna Adamus; Lori Brown; Shayne Andrew; Roberto Meza-Romero; Gregory G Burrows; Arthur A Vandenbark
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-01-25       Impact factor: 4.799

3.  Autoimmunity's next top models.

Authors:  Hartmut Wekerle; Alexander Flügel; Lars Fugger; Georg Schett; David Serreze
Journal:  Nat Med       Date:  2012-01-06       Impact factor: 53.440

4.  Chronic cerebrospinal venous insufficiency: does ultrasound really distinguish multiple sclerosis subjects from healthy controls?

Authors:  Fatih Kantarci; Sait Albayram; Nuri Onat Demirci; Asim Esenkaya; Derya Uluduz; Omer Uysal; Sabahattin Saip; Aksel Siva
Journal:  Eur Radiol       Date:  2011-11-29       Impact factor: 5.315

Review 5.  CCSVI and MS: a statement from the European Society of neurosonology and cerebral hemodynamics.

Authors:  Claudio Baracchini; José M Valdueza; Massimo Del Sette; Galina Baltgaile; Eva Bartels; Natan M Bornstein; Juergen Klingelhoefer; Carlos Molina; Kurt Niederkorn; Mario Siebler; Matthias Sturzenegger; Bernd E Ringelstein; David Russell; Laszlo Csiba
Journal:  J Neurol       Date:  2012-05-31       Impact factor: 4.849

Review 6.  Unique biology of gliomas: challenges and opportunities.

Authors:  Stacey Watkins; Harald Sontheimer
Journal:  Trends Neurosci       Date:  2012-06-08       Impact factor: 13.837

7.  Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study).

Authors:  O Fernández; V Fernández; T Arbizu; G Izquierdo; I Bosca; R Arroyo; J A García Merino; E de Ramón
Journal:  J Neurol       Date:  2010-04-10       Impact factor: 4.849

Review 8.  Myelination and support of axonal integrity by glia.

Authors:  Klaus-Armin Nave
Journal:  Nature       Date:  2010-11-11       Impact factor: 49.962

9.  Subventricular zone microglia transcriptional networks.

Authors:  Sarah C Starossom; Jaime Imitola; Yue Wang; Li Cao; Samia J Khoury
Journal:  Brain Behav Immun       Date:  2010-11-11       Impact factor: 7.217

10.  Much, if not all, of the cortical damage in MS can be attributed to the microglial cell - No.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Mult Scler       Date:  2018-05-14       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.